Sarepta Therapeutics Inc (SRPT)
115.54
-0.97
(-0.83%)
USD |
NASDAQ |
Apr 19, 16:00
117.00
+1.46
(+1.26%)
After-Hours: 20:00
Sarepta Therapeutics Revenue (Quarterly): 396.78M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 396.78M |
| September 30, 2023 | 331.82M |
| June 30, 2023 | 261.24M |
| March 31, 2023 | 253.50M |
| December 31, 2022 | 258.43M |
| September 30, 2022 | 230.27M |
| June 30, 2022 | 233.49M |
| March 31, 2022 | 210.83M |
| December 31, 2021 | 201.46M |
| September 30, 2021 | 189.41M |
| June 30, 2021 | 164.09M |
| March 31, 2021 | 146.93M |
| December 31, 2020 | 145.14M |
| September 30, 2020 | 143.92M |
| June 30, 2020 | 137.36M |
| March 31, 2020 | 113.67M |
| December 31, 2019 | 100.11M |
| September 30, 2019 | 99.04M |
| June 30, 2019 | 94.67M |
| March 31, 2019 | 87.01M |
| December 31, 2018 | 84.42M |
| September 30, 2018 | 78.49M |
| June 30, 2018 | 73.53M |
| March 31, 2018 | 64.60M |
| December 31, 2017 | 57.28M |
| Date | Value |
|---|---|
| September 30, 2017 | 45.95M |
| June 30, 2017 | 35.01M |
| March 31, 2017 | 16.34M |
| December 31, 2016 | 5.421M |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | 1.253M |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | 0.027M |
| September 30, 2014 | 1.059M |
| June 30, 2014 | 2.583M |
| March 31, 2014 | 6.088M |
| December 31, 2013 | 2.626M |
| September 30, 2013 | 4.168M |
| June 30, 2013 | 2.951M |
| March 31, 2013 | 4.474M |
| December 31, 2012 | 7.336M |
| September 30, 2012 | 7.574M |
| June 30, 2012 | 11.21M |
| March 31, 2012 | 11.21M |
| December 31, 2011 | 13.58M |
| September 30, 2011 | 7.524M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
94.67M
Minimum
Jun 2019
396.78M
Maximum
Dec 2023
195.38M
Average
189.41M
Median
Sep 2021
Revenue (Quarterly) Benchmarks
| PTC Therapeutics Inc | 307.06M |
| Vertex Pharmaceuticals Inc | 2.518B |
| Regenxbio Inc | 22.21M |
| CytomX Therapeutics Inc | 26.61M |
| Apellis Pharmaceuticals Inc | 146.38M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 45.66M |
| Total Expenses (Quarterly) | 372.16M |
| EPS Diluted (Quarterly) | 0.76 |
| Enterprise Value | 10.50B |
| Gross Profit Margin (Quarterly) | 88.87% |
| Profit Margin (Quarterly) | 11.51% |
| Earnings Yield | -5.05% |
| Normalized Earnings Yield | -1.806 |